Cell And Gene Therapies: Where Few Standard Rules Apply

Manufacturing, distribution and pricing challenges for cell and gene therapies have been mostly hypothetical – until now. But with no industry standards, the first products to win approval are dictating the complex path forward.

Machinery cogwheels, industry concept

The main rule of the cell and gene therapy market is there are few hard and fast rules when it comes to how to manufacture, distribute, administer and price these potentially curative treatments for cancer and rare diseases.

Without a standard set of rules agreed to by the therapies' developers, the first companies with approved products – along...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cell Therapies

  • Progress Or Hype? A Decade Of Cell Therapy In Japan

     
    • By 

    After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

  • Japan Cell Therapy Hopes Hit By HeartSheet Full Approval Hurdles

     
    • By 

    Despite initial promise, a novel autologous cell transplant therapy for severe heart failure has faced multiple challenges in gaining full approval in Japan, potentially providing learnings for other developers of regenerative medicines.

  • Quick Listen: Scrip's Five Must-Know Things

     
    • By 

    In this week's podcast edition of Five Must-Know Things: global CEO remuneration; another late-stage loss for Merch KgaA; deals shift to smaller M&A, partnering; Bayer’s Parkinson’s bets bear fruit; and India looks to innovate CAR-T models.

  • Bayer's Bets In Parkinson's Start To Bear Fruit

     
    • By 

    The German major is kicking off Phase II trials for a cell therapy and a gene therapy that could be gamechangers for the progressive neurodegenerative disorder that affects more than 10 million people worldwide.

More from Advanced Therapies